MUC1 and neoplasm: We generated cell lines from these KCM mice (KCM cells) [11,14,15] and developed a novel monoclonal antibody, TAB004 (OncoTAb, Inc., Charlotte, NC), which specifically targets the hypoglycosylated/tumor-associated form of MUC1 (tMUC1) [16–19].